Close Menu

NEW YORK (360Dx) – Glycomics startup AccuDava is preparing a clinical study for its glycan-based test for predicting patient response to first-line platinum-based chemotherapy in ovarian cancer.

According to Nahid Razi, AccuDava’s founder and CEO, the company is collaborating with the Fred Hutchinson Cancer Research Center (FHCRC) to obtain clinical samples for a study it hopes to complete later this year.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.